US Supreme Court opens pay-for-delay deals to antitrust scrutiny
Monday, 17 June 2013 (over a year ago)
Ron Knox and Pallavi Guniganti
Pay-for-delay patent settlement deals between drug makers may violate the US antitrust laws even if the patent at issue is still technically active and valid, the Supreme Court ruled today.
US Supreme Court
Premium Subscription required to view this article
This content can only be accessed by Premium subscribers.
This content is part of the GCR archive and can only be accessed by subscribers with a Premium Subscription.
If you are a subscriber, please login: